“we expect a similar trajectory as macitentan, OPSUMIT and Tadalafil (ph) become standard of care clearly established in this area.”

In context

“m future of this business into 2024. We are working towards the combination of macitentan, OPSUMIT with Tadalafil, which the trademark will be OPSYNVI. And that would be another option for patients there to enhance compliance. And in my talks with physicians treating pulmonary hypertension, they seem very positive about it, and we expect an approval of that combination in 2024. So that's the outlook for our pulmonary franchise. Are we looking at other areas there? There, we are looking at the space and see if there are potential opportunities to be able to improve the standard of care. And we continue to look to see how we can continue to extend the success of our pulmonary franchise into the future. But overall, we're very happy with the trajectory of our pulmonary franchise in 2023. And we expect a similar trajectory as macitentan, OPSUMIT and Tadalafil (ph) become standard of care clearly established in this area. Operator: Thank you. Next question today is coming from Louise Chen from Cantor Fitzgerald. Your line is now live. Louise Chen: Hi. Thank you for taking my question here. I just wanted to ask you with respect to your oncology franchise. Do you have any thoughts on CAR-Ts for autoimmune disease at all? And then secondly, radiopharmaceutical? Joaquin Duato: So thank you, Louise and we have a strong oncology franchise in different areas. I commented that here in prostate cancer with ERLEADA that I discussed before. We'll see data in high risk localized prostate cancer in 2024 with the addition of Ambrx now and antibody drug conjugate in this area. We are very, very excited about RYBREVANT and the combination of RYBREVANT plus lazertinib. We have Phase 3 studies completed. We expect -- we hav”